M
Miromatrix Medical
Engaged in the development of fully biological human organs and organ-derived biological products
About Miromatrix Medical
Miromatrix is a pioneering company focused on eliminating the organ transplant waiting list by bioengineering transplantable organs such as liver, kidney, and heart. The company operates in the healthcare and biotechnology markets, serving patients in need of organ transplants and medical institutions that perform these procedures. Miromatrix employs a proprietary perfusion recellularization process, which involves using decellularized organs as templates to support the growth and differentiation of cells into functional organs. This innovative approach aims to address the critical shortage of transplantable organs, offering a sustainable and scalable solution to a pressing medical issue.
Read full description
Miromatrix's business model revolves around research and development, securing grants, and forming strategic partnerships with healthcare providers and research institutions. The company generates revenue through grants, such as the $1.9 million NIH grant for bioengineered liver development, and potential future sales of bioengineered organs. By focusing on cutting-edge biotechnology and regenerative medicine, Miromatrix is positioned to make a significant impact on the organ transplant landscape.
At a glance
- Status
- Acquired
- Founded
- 2009
- Headquarters
- Eden Prairie, United States
- Employees
- 73
- Open positions
- None listed
- Dealroom signal
- 73.6/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning Miromatrix Medical.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITIONOther financing | Oct 2023 | $91M | $91M | United Therapeutics | ↗ |
| IPOOther financing | Jun 2021 | $0 | — | Undisclosed | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Miromatrix Medical is 2.9K monthly website visits, up 320.3% over the last three months. Miromatrix Medical's team grew 1.4% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
National Institute of Diabetes and Digestive and Kidney Diseases
Series A1 investor entered at this stage
Brightstone Venture Capital
Series B and later1 investor entered at this stage
CareDx
Other known investors4 additional known investors
United Therapeutics
University of Minnesota Twin Cities
DaVita Venture Group
Gravity Fund
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Miromatrix Medical on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Miromatrix Medical’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.